Common name
N-butylacetamide
IUPAC name
N-butylacetamide
SMILES
CCCCNC(=O)C
Common name
N-butylacetamide
IUPAC name
N-butylacetamide
SMILES
CCCCNC(=O)C
INCHI
InChI=1S/C6H13NO/c1-3-4-5-7-6(2)8/h3-5H2,1-2H3,(H,7,8)
FORMULA
C6H13NO
Common name
N-butylacetamide
IUPAC name
N-butylacetamide
Molecular weight
115.174
clogP
0.759
clogS
-1.813
Frequency
0.0014
HBond Acceptor
1
HBond Donor
1
Total PolarSurface Area
29.1
Number of Rings
0
Rotatable Bond
3
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00753 | Benzylpenicilloyl Polylysine |
|
Acetamides; | For use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G). |
| FDBD01424 | Peramivir |
|
Antiviral Agents; Enzyme Inhibitors; | Investigated for use/treatment in influenza. |
| FDBD01652 | Cobicistat |
|
Anti-HIV Agents; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP3A Inhibitors; CYP2D6 Inducers; CYP2D6 Inducers (strong); | Cobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. |
| FDBD01789 | Sacubitril |
|
Cardiovascular System; Agents Acting on the Renin-Angiotensin System; | Used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV). |
4 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 3duy_ligand_4_2239.mol2 | 3duy | 1 | -6.65 | C(CC(C)C)NC(=O)C | 9 |
| 4trw_ligand_4_3611.mol2 | 4trw | 1 | -6.59 | C(C)(C)CCNC(=O)C | 9 |
| 1ym4_ligand_4_141.mol2 | 1ym4 | 1 | -6.57 | CC(=O)NCCC(C)C | 9 |
| 2g94_ligand_4_2136.mol2 | 2g94 | 1 | -6.54 | C(C)(C)CCNC(=O)C | 9 |
| 2zu4_ligand_4_1773.mol2 | 2zu4 | 1 | -6.53 | CC(=O)NCCC(C)C | 9 |
| 2zu5_ligand_4_2850.mol2 | 2zu5 | 1 | -6.53 | C(C)(C)CCNC(=O)C | 9 |
| 2hob_ligand_4_1886.mol2 | 2hob | 1 | -6.52 | C(C)(C)CCNC(=O)C | 9 |
212 ,
22
